AR066266A1 - DERIVADOS DE CROMENO Y DE TETRAHIDRONAFTALENO uTILES PARA EL TRATAMIENTO DEL DOLOR - Google Patents

DERIVADOS DE CROMENO Y DE TETRAHIDRONAFTALENO uTILES PARA EL TRATAMIENTO DEL DOLOR

Info

Publication number
AR066266A1
AR066266A1 ARP080101710A ARP080101710A AR066266A1 AR 066266 A1 AR066266 A1 AR 066266A1 AR P080101710 A ARP080101710 A AR P080101710A AR P080101710 A ARP080101710 A AR P080101710A AR 066266 A1 AR066266 A1 AR 066266A1
Authority
AR
Argentina
Prior art keywords
6alkyl
6alkoxy
acid
6haloalkyl
phenyl
Prior art date
Application number
ARP080101710A
Other languages
English (en)
Spanish (es)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39876087&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR066266(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR066266A1 publication Critical patent/AR066266A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D261/00Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrane Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ARP080101710A 2007-04-23 2008-04-23 DERIVADOS DE CROMENO Y DE TETRAHIDRONAFTALENO uTILES PARA EL TRATAMIENTO DEL DOLOR AR066266A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US91331207P 2007-04-23 2007-04-23

Publications (1)

Publication Number Publication Date
AR066266A1 true AR066266A1 (es) 2009-08-05

Family

ID=39876087

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080101710A AR066266A1 (es) 2007-04-23 2008-04-23 DERIVADOS DE CROMENO Y DE TETRAHIDRONAFTALENO uTILES PARA EL TRATAMIENTO DEL DOLOR

Country Status (23)

Country Link
US (2) US8143408B2 (OSRAM)
EP (1) EP2158198B1 (OSRAM)
JP (1) JP2010525056A (OSRAM)
KR (1) KR20100015827A (OSRAM)
CN (1) CN101687860B (OSRAM)
AR (1) AR066266A1 (OSRAM)
AU (1) AU2008241610B2 (OSRAM)
BR (1) BRPI0810354A2 (OSRAM)
CA (1) CA2685141A1 (OSRAM)
CL (1) CL2008001170A1 (OSRAM)
CO (1) CO6251361A2 (OSRAM)
EC (1) ECSP099706A (OSRAM)
IL (1) IL201309A0 (OSRAM)
MX (1) MX2009011364A (OSRAM)
MY (1) MY146662A (OSRAM)
NZ (1) NZ581353A (OSRAM)
PE (1) PE20090727A1 (OSRAM)
RU (1) RU2460730C2 (OSRAM)
SA (1) SA08290245B1 (OSRAM)
TW (1) TW200848037A (OSRAM)
UY (1) UY31046A1 (OSRAM)
WO (1) WO2008130320A2 (OSRAM)
ZA (1) ZA200907137B (OSRAM)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SA08290245B1 (ar) * 2007-04-23 2012-02-12 استرازينيكا ايه بي مشتقات كربو كساميد جديدة من -n (8-اريل رباعي هيدرو نفثالين غير متجانس- 2- يل) أو -n (5-اريل كرومان غير متجانس -3-يل) لعلاج الألم
AR074760A1 (es) * 2008-12-18 2011-02-09 Metabolex Inc Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
US8748623B2 (en) * 2009-02-17 2014-06-10 Syntrix Biosystems, Inc. Pyridinecarboxamides as CXCR2 modulators
JP2013508456A (ja) * 2009-10-26 2013-03-07 シグナル ファーマシューティカルズ, エルエルシー ヘテロアリール化合物の合成方法および精製方法
UA103272C2 (uk) 2009-12-11 2013-09-25 Ф. Хоффманн-Ля Рош Аг 2-аміно-5,5-дифтор-5,6-дигідро-4h-оксазини як інгібітори bace1 і/або bace2
KR20120130104A (ko) 2010-02-01 2012-11-28 닛뽕 케미파 가부시키가이샤 Gpr119 작동약
US8779149B2 (en) 2010-08-23 2014-07-15 Syntrix Biosystems, Inc. Aminopyridine- and aminopyrimidinecarboxamides as CXCR2 modulators
WO2012039657A1 (en) * 2010-09-22 2012-03-29 Astrazeneca Ab Novel chromane compound for the treatment of pain disorders
CN102408385B (zh) * 2011-06-20 2014-06-18 雅本化学股份有限公司 一种2-取代-2h-1,2,3-三氮唑衍生物的制备方法
CN102408386B (zh) * 2011-07-27 2014-05-07 雅本化学股份有限公司 2,4-二取代-2h-1,2,3-三氮唑衍生物的制备方法
CN102603659B (zh) * 2012-03-01 2014-03-26 雅本化学股份有限公司 1-取代-4-溴-1h-1,2,3-三氮唑-5-羧酸及其制备方法
KR102226587B1 (ko) * 2013-01-31 2021-03-11 버텍스 파마슈티칼스 인코포레이티드 나트륨 채널의 조절제로서의 퀴놀린 및 퀴나졸린 아미드
US10046002B2 (en) 2013-08-02 2018-08-14 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
US10561676B2 (en) 2013-08-02 2020-02-18 Syntrix Biosystems Inc. Method for treating cancer using dual antagonists of CXCR1 and CXCR2
US8969365B2 (en) 2013-08-02 2015-03-03 Syntrix Biosystems, Inc. Thiopyrimidinecarboxamides as CXCR1/2 modulators
KR20160118345A (ko) * 2014-02-06 2016-10-11 애브비 인코포레이티드 6-헤테로아릴옥시- 및 6-아릴옥시-퀴놀린-2-카복사미드 및 이의 용도
KR102412146B1 (ko) 2015-02-11 2022-06-22 주식회사 아이엔테라퓨틱스 소디움 채널 차단제
AU2016351526B2 (en) 2015-11-13 2019-02-21 In Therapeutics Sodium channel blocker
CN105541774B (zh) * 2016-01-13 2018-06-15 华中师范大学 3,4-二氢香豆素类化合物及其制备方法和用途
US11485733B2 (en) * 2017-06-30 2022-11-01 Bayer Animal Health Gmbh Azaquinoline derivatives
EP3740481B9 (en) 2018-01-19 2024-10-23 Cytokinetics, Inc. Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors
AU2019232437A1 (en) 2018-03-07 2020-10-08 Bayer Aktiengesellschaft Identification and use of ERK5 inhibitors
EP3814343B1 (en) 2018-06-26 2023-01-11 Cytokinetics, Inc. Cardiac sarcomere inhibitors
EP3814342B1 (en) 2018-06-26 2022-07-27 Cytokinetics, Inc. Cardiac sarcomere inhibitors
FI3851436T3 (fi) 2018-09-10 2024-09-03 Kaken Pharma Co Ltd Uusi heteroaromaattinen amidijohdannainen ja sitä sisältävä lääke
EP3972963A1 (en) 2019-05-21 2022-03-30 Bayer Aktiengesellschaft Identification and use of kras inhibitors
MX2023010125A (es) 2021-03-04 2023-09-11 Cytokinetics Inc Inhibidores del sarcomero cardiaco.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8904361D0 (sv) * 1989-12-22 1989-12-22 Astra Ab New chroman and thiochroman derivatives
WO1994012493A1 (en) * 1992-11-25 1994-06-09 Sandoz, Ltd. 2,2-dialkyl- and 2,2-dialkyl-3,4-dihydro-3-hydroxy-2h-1-benzopyr ans, their use as pharmaceuticals
JPH0827153A (ja) * 1994-07-12 1996-01-30 Nippon Kayaku Co Ltd アザクロマン誘導体及びその用途
SE9601110D0 (sv) * 1996-03-22 1996-03-22 Astra Ab Substituted 1,2,3,4-tetrahydronaphthalene derivatives
GB9713804D0 (en) * 1997-06-30 1997-09-03 Novo Nordisk As Particulate polymeric materials and their use
JPH1135569A (ja) 1997-07-22 1999-02-09 Meiji Milk Prod Co Ltd ポリフェノール化合物及びこれを含有する医薬
SE9702799D0 (sv) 1997-07-25 1997-07-25 Astra Ab New compounds
SE9703378D0 (sv) * 1997-09-18 1997-09-18 Astra Ab New compounds
SE9703377D0 (sv) * 1997-09-18 1997-09-18 Astra Ab New compounds
TW200524888A (en) * 2003-08-08 2005-08-01 Vertex Pharma Compositions useful as inhibitors of voltage-gated ion channels
US7615563B2 (en) * 2003-08-08 2009-11-10 Gonzalez Iii Jesus E Compositions useful as inhibitors of voltage-gated sodium channels
EP1877385A1 (en) * 2005-05-04 2008-01-16 Vertex Pharmaceuticals Incorporated Pyrimidines and pyrazines useful as modulators of ion channels
EP2044019A1 (en) * 2006-07-12 2009-04-08 Astra Zeneca AB 3-oxoisoindoline-1-carboxamide derivatives as analgesic agents
SA08290245B1 (ar) * 2007-04-23 2012-02-12 استرازينيكا ايه بي مشتقات كربو كساميد جديدة من -n (8-اريل رباعي هيدرو نفثالين غير متجانس- 2- يل) أو -n (5-اريل كرومان غير متجانس -3-يل) لعلاج الألم

Also Published As

Publication number Publication date
AU2008241610B2 (en) 2011-08-18
SA08290245B1 (ar) 2012-02-12
JP2010525056A (ja) 2010-07-22
US8143408B2 (en) 2012-03-27
EP2158198A2 (en) 2010-03-03
PE20090727A1 (es) 2009-07-23
CN101687860A (zh) 2010-03-31
IL201309A0 (en) 2010-05-31
RU2009138137A (ru) 2011-05-27
AU2008241610A1 (en) 2008-10-30
EP2158198B1 (en) 2013-03-20
MX2009011364A (es) 2009-11-05
US20100137322A1 (en) 2010-06-03
CL2008001170A1 (es) 2009-05-22
EP2158198A4 (en) 2012-01-04
CO6251361A2 (es) 2011-02-21
CN101687860B (zh) 2012-07-04
MY146662A (en) 2012-09-14
TW200848037A (en) 2008-12-16
CA2685141A1 (en) 2008-10-30
ECSP099706A (es) 2009-11-30
WO2008130320A2 (en) 2008-10-30
NZ581353A (en) 2012-02-24
WO2008130320A3 (en) 2008-12-18
ZA200907137B (en) 2010-07-28
US20120238579A1 (en) 2012-09-20
UY31046A1 (es) 2008-11-28
BRPI0810354A2 (pt) 2014-10-21
RU2460730C2 (ru) 2012-09-10
KR20100015827A (ko) 2010-02-12

Similar Documents

Publication Publication Date Title
AR066266A1 (es) DERIVADOS DE CROMENO Y DE TETRAHIDRONAFTALENO uTILES PARA EL TRATAMIENTO DEL DOLOR
ES2645638T3 (es) Derivados de 5-fenoxi-3H-pirimidin-4-ona y su uso como inhibidores de la transcriptasa inversa del VIH
ES2683445T3 (es) Benzamidas sustituidas para el tratamiento de artrópodos
RU2403251C2 (ru) Производные 2, 4-ди(гетеро)ариламинопиримидина в качестве ингибиторов zap-70
ES2438240T3 (es) Nuevos derivados de biaril benzoimidazol y composición farmacéutica que los comprenden
US10442778B2 (en) N1-phenylpropane-1,2-diamine compounds with selective activity in voltage-gated sodium channels
AR064505A1 (es) Derivados ester o amida de imidazolilo, composiciones farmaceuticas que los comprenden,proceso de preparacion, y usos como medicamentos para el tratamiento de enfermedades inflamatorias, entre otras.
AR078157A1 (es) Derivados de pirazol-[4,5-d]pirrolo[2,3-b]piridina inhibidores de tirosinquinasas jak 2, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer
AR041467A1 (es) Indol-3-carboxamidas como activadores de glucoquinasa (gk)
RU2016115803A (ru) Замещенные никотинимидные ингибиторы втк, их получение и применение в терапии раковых, воспалительных и аутоиммунных заболеваний
PE20081806A1 (es) Imidazo- y triazolopirimidinas sustituidas
JPWO2008129951A1 (ja) 新規なジベンジルアミン構造を有するピリミジン化合物及びこれを含有する医薬
RU2015134558A (ru) Моноциклическое пиридиновое производное
PE20091687A1 (es) Derivados de piridina o pirazina como inhibidores de cinasa-pi-3
JP2019536766A (ja) 2−置換芳香族環−ピリミジン系誘導体及びその調製と医学的用途
BRPI1007456A2 (pt) derivados de azaespiranil-alquilcarbamatos de compostos heterocíclicos com 5 membros, o respectivo preparo e a respectiva aplicação em terapêutica
CN102858177A (zh) 儿茶酚-o-甲基转移酶抑制剂及其在治疗精神障碍中的用途
JP2023027160A (ja) NotchシグナリングのエンハンサーならびにNotchのアップレギュレーションにより治療可能ながんおよび悪性腫瘍の治療におけるその使用
WO2014210456A1 (en) Pyrazoline dihydroquinolones, pharmaceutical compositions, and uses
JP2016501869A (ja) α−(3,5−ジメトキシベンジリデン)−α’−炭化水素基メチレン環状ケトン
JP7681599B2 (ja) 選択的cdk4/6阻害剤のがん治療薬
AU2018215089B2 (en) Anti-fibrotic compounds
JP5319457B2 (ja) 新規なジベンジルアミン構造を有するピリミジン化合物及びこれを含有する医薬
CN103006449A (zh) 酪氨酸酶抑制剂及其制备方法
EP2714667A2 (en) Aminooxazole inhibitors of cyclin dependent kinases

Legal Events

Date Code Title Description
FA Abandonment or withdrawal